| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/22/2013 | CN102134214B Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| 05/22/2013 | CN102125566B Pharmaceutical composition comprising cycloartenyl ferulate |
| 05/22/2013 | CN102119034B Tablet quickly disintegrating in the oral cavity and method for producing the same |
| 05/22/2013 | CN102100684B Application of secoisolariciresinol in preparation of medicament for treating depression and anxiety |
| 05/22/2013 | CN102080084B Human miR-125a-5p antisense nucleotide and application thereof |
| 05/22/2013 | CN102080082B Human miR-129* antisensenucleic acid and applications thereof |
| 05/22/2013 | CN102058829B Medicine composition and detection method of preparations of medicine composition |
| 05/22/2013 | CN102036959B Polysubstituted 2-aryl-6-phenyl-imidazo[l,2-a] pyridine derivatives, and preparation and therapeutic use thereof |
| 05/22/2013 | CN102028860B Chinese medicinal herb preparation for treating insomnia |
| 05/22/2013 | CN101953864B Cynanchum otophyllum aglycone and medical application of extractive containing same |
| 05/22/2013 | CN101934069B Application of neuroglobin in promoting neurite growth |
| 05/22/2013 | CN101910110B Preparation method of rivastigmine, its intermediates and preparation method of the intermediates |
| 05/22/2013 | CN101862331B New use of methyl liensinine |
| 05/22/2013 | CN101849006B Improved antibody molecule |
| 05/22/2013 | CN101848725B 组合物 The composition |
| 05/22/2013 | CN101835756B 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive MGLUR2 -receptor modulators |
| 05/22/2013 | CN101821257B 5-HT7 receptor antagonists |
| 05/22/2013 | CN101678047B Remedy and diagnostic agent for mitochondrial dysfunction brain disease |
| 05/22/2013 | CN101622241B Benzimidazole compound and pharmaceutical use thereof |
| 05/22/2013 | CN101544579B Use and preparation method of 4-(-2-acetoxybenzoyl)aminobutyric acid and ester derivative thereof |
| 05/21/2013 | US8445494 Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| 05/21/2013 | US8445438 Compositions comprising capture peptides for A β-amyloid peptide |
| 05/21/2013 | US8445425 Urocortin-III and uses thereof |
| 05/21/2013 | US8445233 PGC-1β, a novel PGC-1 homologue and uses therefor |
| 05/21/2013 | US8445015 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 05/21/2013 | CA2583397C Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| 05/21/2013 | CA2559802C Method for stimulating the immune, inflammatory or neuroprotective response |
| 05/21/2013 | CA2477675C Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein |
| 05/21/2013 | CA2460092C A method of diagnosis and treatment and agents useful for same |
| 05/21/2013 | CA2412436C Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 05/21/2013 | CA2399080C Humanized anti-ccr2 antibodies and methods of use therefor |
| 05/21/2013 | CA2396688C Glycosidase inhibitors and methods of synthesizing same |
| 05/17/2013 | CA2758556A1 Pharmaceutical composition of amphetamine mixed salts |
| 05/16/2013 | WO2013071282A1 Pkc activators and combinations thereof |
| 05/16/2013 | WO2013071281A1 Esters of dcpla and methods of treatment using the same |
| 05/16/2013 | WO2013071267A1 Compositions and methods for treating alzheimer's disease |
| 05/16/2013 | WO2013071077A1 The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies |
| 05/16/2013 | WO2013071061A1 Compositions and methods for increasing stress resilience |
| 05/16/2013 | WO2013070961A1 Modulators of atp-binding cassette transporters |
| 05/16/2013 | WO2013070879A1 Methods for treating spinal cord injury with lpa receptor antagonists |
| 05/16/2013 | WO2013070821A1 Methods and compositions for treating diseases, disorders or injury of the nervous system |
| 05/16/2013 | WO2013070236A1 Methods and compositions for treating hemorrhoids while providing local anesthetic and anti-inflammatory effects |
| 05/16/2013 | WO2013070107A1 5h-dibenzo[b,e][1,4]diazepine derivatives and use thereof |
| 05/16/2013 | WO2013070011A1 Pharmaceutical composition for the prevention or treatment of neurological diseases comprising an ampa receptor endocytosis inhibitor |
| 05/16/2013 | WO2013069861A1 Pharmaceutical composition for preventing and treating neuropathic pain containing gaba nerve cells differentiated and induced by treating adipose tissue-derived stem cells with cbm-1078 as active ingredient |
| 05/16/2013 | WO2013069765A1 Nitrogenated heterocyclic compound |
| 05/16/2013 | WO2013069339A1 Puncture pain alleviating external preparation |
| 05/16/2013 | WO2013068935A1 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
| 05/16/2013 | WO2013068785A1 Indanone and indandione derivatives and heterocyclic analogs |
| 05/16/2013 | WO2013068592A1 Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide |
| 05/16/2013 | WO2013068504A1 Apotransferrin for the treatment of brain stroke |
| 05/16/2013 | WO2013068489A1 Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a |
| 05/16/2013 | WO2013068470A1 Inhibitors of phosphodiesterase type 10a |
| 05/16/2013 | WO2013068431A1 New treatment for neurodegenerative diseases |
| 05/16/2013 | WO2013068330A1 Composition for treating or preventing neurodegenerative disorders |
| 05/16/2013 | WO2013067770A1 Compositions and methods for treating traumatic brain injury |
| 05/16/2013 | WO2013067710A1 Nampt inhibitors |
| 05/16/2013 | WO2013067612A1 Pharmaceutical composition for the preparation of a drug for treating neuropathic pain, chronic degenerative disease-related pain and post-operative pain in animals |
| 05/16/2013 | WO2013067591A1 Topical formulations for pain management |
| 05/16/2013 | WO2012173442A3 Composition containing bee venom phospholipase as an active ingredient treating prion disease |
| 05/16/2013 | WO2012054721A8 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
| 05/16/2013 | US20130123741 Flexible sterile bag containing pharmaceutical products and diluant separately and method of making the same |
| 05/16/2013 | US20130123295 Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists |
| 05/16/2013 | US20130123251 Benzoxazine derivatives and uses thereof |
| 05/16/2013 | US20130123238 Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders |
| 05/16/2013 | US20130122116 Pain reliever composition |
| 05/16/2013 | US20130122098 Method and composition to improve absorption of therapeutic agents |
| 05/16/2013 | US20130122076 Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease |
| 05/16/2013 | US20130122018 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 05/16/2013 | US20130121974 Methods of making enhanced, autologous fat grafts |
| 05/16/2013 | CA2856235A1 Esters of dcpla and methods of treatment using the same |
| 05/16/2013 | CA2855932A1 Pkc activators and combinations thereof |
| 05/16/2013 | CA2855669A1 Compositions and methods for treating alzheimer's disease |
| 05/16/2013 | CA2855510A1 Nampt inhibitors |
| 05/16/2013 | CA2854949A1 Apotransferrin for the treatment of brain stroke |
| 05/16/2013 | CA2854631A1 Indolealkylamino-withasteroid conjugates and method of use |
| 05/16/2013 | CA2852991A1 Modulators of atp-binding cassette transporters |
| 05/16/2013 | CA2852820A1 Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a |
| 05/16/2013 | CA2852604A1 Inhibitors of phosphodiesterase type 10a |
| 05/16/2013 | CA2846568A1 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
| 05/15/2013 | EP2592082A1 Heteroaryl amide analogues as p2x7 antagonists |
| 05/15/2013 | EP2592075A1 Pyridazine compounds for the treatment of inflammatory diseases |
| 05/15/2013 | EP2591823A1 Composition for treating or preventing neurodegenerative disorders |
| 05/15/2013 | EP2591822A1 Treatment of diseases |
| 05/15/2013 | EP2591790A1 T cell apoptosis inducer |
| 05/15/2013 | EP2591785A1 Use of 5 -androstane (alkyl)-3 ,5,6 -triol in preparing neuroprotective drugs |
| 05/15/2013 | EP2590984A1 Anellated pyridine compounds |
| 05/15/2013 | EP2590980A1 Fused heterocyclic derivatives as s1p modulators |
| 05/15/2013 | EP2590972A2 Chemical compounds |
| 05/15/2013 | EP2590969A2 Therapeutic agents 976 |
| 05/15/2013 | EP2590963A1 (3 -methylpyrrolidin- 3 - yl) methyl pyridinyl ether derivatives and their use as nk-3 receptor antagonists |
| 05/15/2013 | EP2590961A1 Piperidinyl pyrimidine amides as kv7 potassium channel openers |
| 05/15/2013 | EP2590957A2 Chemical compounds |
| 05/15/2013 | EP2590955A1 Spiro-cyclic amine derivatives as s1p modulators |
| 05/15/2013 | EP2590954A1 Bisaryl (thio)morpholine derivatives as s1p modulators |
| 05/15/2013 | EP2590946A1 Bipyridyl derivatives useful for the treatment of kinase - induced diseases |
| 05/15/2013 | EP2590942A1 Rho kinase inhibitors |
| 05/15/2013 | EP2590682A1 Delivery of hydrophilic peptides |
| 05/15/2013 | EP2590661A1 Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients. |
| 05/15/2013 | EP2590658A2 Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates |